Erasca, Inc. (ERAS) is listed on NASDAQ in Pharmaceutical Stocks. It is $18.03, -7.49%, with a $6.3B market cap. RSI is 47.2, neutral. The latest reported quarter missed estimates. Insiders were net buyers across the listed trades.
Technical Analysis
RSI (14) 47.2 Neutral
Market Cap $6.3B
Volume 2.2M
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $-227.5M
EPS $-0.74
P/E Ratio -24.4x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Garner Ebun | Chief Legal Officer | Sell | 80,000 | $16.40 | $1.3M | 2026 Apr 1 |
| Morris Shannon | Chief Medical Officer | Sell | 20,000 | $15.04 | $300,760 | 2026 Mar 4 |
| Casdin Alexander W. | Director | Buy | 80,000 | $2.27 | $181,600 | 2024 May 21 |
| Start Valerie Denise Harding | Director | Buy | 10,000 | $1.85 | $18,500 | 2023 Dec 6 |
| Lim Jonathan E | Chairman & CEO | Buy | 1,000,000 | $1.70 | $1.7M | 2023 Dec 6 |
| Casdin Alexander W. | Director | Buy | 30,000 | $1.66 | $49,800 | 2023 Dec 4 |
| Lim Jonathan E | Chairman & CEO | Buy | 1,000,000 | $2.03 | $2.0M | 2023 Oct 5 |
| Lim Jonathan E | Chairman & CEO | Buy | 100,000 | $2.75 | $275,000 | 2023 Jun 8 |
| Casdin Alexander W. | Director | Buy | 20,000 | $2.76 | $55,200 | 2023 Apr 10 |
| Lim Jonathan E | Chairman & CEO | Buy | 100,000 | $2.84 | $284,000 | 2023 Mar 28 |
| Lim Jonathan E | Chairman & CEO | Buy | 60,000 | $3.86 | $231,600 | 2023 Jan 10 |
| Start Valerie Denise Harding | Director | Buy | 10,000 | $4.64 | $46,400 | 2022 Dec 21 |
| Bristol James Arthur | Director | Buy | 20,000 | $4.14 | $82,800 | 2022 Dec 21 |
| Casdin Alexander W. | Director | Buy | 20,000 | $4.87 | $97,400 | 2022 Dec 15 |
| Lim Jonathan E | Chairman & CEO | Buy | 40,000 | $4.99 | $199,600 | 2022 Dec 14 |
| Cormorant Global Healthcare Master Fund, LP | Director | Buy | 307,692 | $6.50 | $2.0M | 2022 Dec 13 |
| Chen Bihua | Director | Buy | 0 | $0.00 | $666,000 | 2021 Aug 10 |
| Cormorant Private Healthcare Fund II, LP | 10% Owner | Buy | 950,000 | $16.00 | $15.2M | 2021 Jul 20 |
| Start Valerie Denise Harding | Director | Buy | 2,000 | $16.00 | $32,000 | 2021 Jul 20 |
| Garner Ebun | General Counsel | Buy | 900 | $16.00 | $14,400 | 2021 Jul 20 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $113.77 | 55.4 | $12.3B |
| | $76.62 | 35.2 | $15.0B |
| | $84.95 | 54.8 | $12.0B |
| | $72.17 | 37.1 | $10.0B |
| | $32.15 | 38.6 | $3.8B |
Take ERAS further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ERAS in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Erasca, Inc. next reports.
Set alerts on ERAS
Get notified when Erasca, Inc. hits your price targets or technical conditions are met.
Get Started Free